**US finds first case of mad cow disease**

At least 36 nations banned the import of US beef after the US Department of Agriculture (USDA) reported the first case of bovine spongiform encephalopathy (BSE), or mad cow disease, in the US in December.

Meat from the infected Holstein cow---and 19 others slaughtered on the same day---was shipped to eight US states and to Guam. About 10,000 pounds of beef has since been recalled. US officials said the cow originated from the Canadian province of Alberta, also the site of Canada\'s first case of BSE last May (*Nat. Med.* **9**, 809; 2003). In January, the USDA announced plans to kill 450 quarantined calves, including the infected Holstein\'s offspring.

The agency also set new regulations, including banning meat from \'downer\' cows---those that are too sick or old to stand or walk. Also banned are small intestines, and the head and spinal tissue from cows older than 30 months. In addition, meat will only be shipped from slaughterhouses after testing negative for BSE.

Meanwhile, there is new concern that vCJD, the human version of BSE, can be spread through blood transfusions. British health officials are investigating the death last fall of a patient who received blood from a donor who later died of vCJD. More than 150 cases of vCJD, most of them in the UK, have been reported worldwide. ---*AS*

**FDA bans ephedra sales**

The US Food and Drug Administration (FDA) in December banned sales of dietary supplements containing ephedra, an herb widely used to aid weight loss and enhance athletic performance.

Ephedra\'s ability to speed up the body\'s metabolism has been linked to reports of heart attack, stroke, seizures and sudden death (*Nat. Med.* **9**, 634--635; 2003). After reviewing thousands of reports of adverse reactions, the FDA ruled that the drug poses an "unreasonable risk of illness or injury," and is urging consumers to stop buying and using ephedra-based supplements immediately.

Manufacturers of the supplement are expected to challenge the ban, claiming the drug is safe when used as directed. Sales of ephedra spiked after the ban was announced, as anxious consumers stocked up on their favorite products. ---*PL*

**Asian nations face bird flu, SARS**

Chinese health officials have confirmed the return of severe acute respiratory syndrome (SARS) to the nation. As of 15 January, China reported three cases of SARS, all in the Guangdong province where the illness first surfaced in November 2002.China is culling civet cats as a precaution against SARS.Reuters/China Photo ASW/DLChina Guangzhou

Chinese officials immediately ordered the culling---by boiling, drowning, electrocuting or burning---of 10,000 civet cats, which many Chinese scientists suspect as the source of SARS, as a protective measure. Chinese officials also said they would kill rats and cockroaches. However, the World Health Organization (WHO) cautioned that slaughtering civets, which are related to mongooses, could help spread infection and destroy scientific evidence. Chinese officials banned the sale of civets last year when SARS was on the rise, but lifted the ban in August.

There have been five suspected cases of SARS since the epidemic sickened 8,000 and killed 774 in 27 countries last year. Two other cases appeared in late 2003---one in Singapore in September and another in Taiwan in December. Both involved researchers who had accidentally become infected while working with the virus.

Meanwhile, South Korea, Vietnam and Japan reported outbreaks among poultry farms of the avian influenza virus H5N1. The WHO confirmed that the virus was responsible for three human deaths in Vietnam and is investigating several other cases. As of 15 January, however, the agency said there was no evidence of human-to-human transmission. ---*AS*

**EU drops cloning ban**

The European Parliament backed down from a proposed ban on therapeutic human cloning after the European Council declared it unacceptable. During negotiations in December 2003, the two bodies of the European Union (EU) agreed on a compromise, saying the new rules will "not interfere with member states\' decisions" on the use of specific types of cells.

Citing health concerns, the Parliament had adopted the proposal to prohibit transplantation of cells derived from human clones. But the Council insisted that individual countries such as Sweden and the UK maintain their right to allow the procedure.

The compromise cleared the way for much-awaited EU regulation on the use of all types of human tissues and cells. Those rules---which individual European countries can only tighten---regulate donation, testing, processing, storage and distribution of all human material, except whole organs and blood. Public and private users have to abide by the same quality and safety standards, which proscribe, among other things, that donors may not gain financially from their generosity.

The European biotech industry, which had lobbied hard for some form of legislation, welcomed the compromise, expressing hope that market regulation of industrial products based on human tissues and cells would soon follow. ---*PV*

**NIH resets conflict-of-interest limits**

The US National Institutes of Health (NIH) increased the financial conflict-of-interest threshold, effective 4 February, from \$5,000 to \$10,000 for extramural researchers who participate in the peer-review process. The rules, which have not been updated since 1985, are necessary to reiterate that outside researchers are not accountable to the same conflict-of-interest rules as federal workers, the agency says.

Meanwhile, a US House committee and a Senate subcommittee have both asked NIH director Elias Zerhouni to produce documents on agency scientists who served as paid consultants to drug companies with NIH funding. The request came a day after the *Los Angeles Times* published a high-profile article on NIH employees\' conflicts of interest.

In a December letter to the House committee, Zerhouni said he had begun a review of all nongovernmental payments made to NIH employees since 1 January 1999, and would put forward recommendations for improving the agency\'s ethical policies within 90 days.

The controversy comes months after a congressional committee said NIH researchers, including former National Cancer Institute director Richard Klausner, had broken federal criminal laws by taking \'lecture awards\' from NIH grantees (*Nat. Med.* **9**, 984; 2003). ---*AS*
